Compare DuPont de Nemours Inc (DD) vs Medtronic PLC (MDT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DuPont de Nemours Inc vs Medtronic PLC — how do they compare? DuPont de Nemours Inc trades at $131.75 (market cap $17.70B), while Medtronic PLC trades at $87.9 (market cap $109.38B). The key difference: Medtronic PLC is far larger — about 6.2× DuPont de Nemours Inc's market cap, and Medtronic PLC pays the higher dividend (3.37%). Which is the better fit depends on your goals — on Pluang, investors hold DuPont de Nemours Inc for 89 Days and Medtronic PLC for 63 Days on average.
| DD | MDT | |
|---|---|---|
Market Cap | $17.70B | $109.38B |
Volume | 638,303 | 55,890,185 |
Sector | Basic Materials | Health |
52-Week High | $154.59 | $105.35 |
52-Week Low | $92.49 | $73.75 |
Typical Hold Time | 89 Days | 63 Days |
Enterprise Value | $19.09B | $128.71B |
Dividend Yield | 1.83% | 3.37% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DuPont (DD) trades at $131.08, down 1.65% on the day, with neutral technical signals from moving averages and oscillators. The company shows mixed fundamentals with recent earnings beats but declining revenue from $12.4B in 2024 to $6.85B in 2025, resulting in a net loss of $779M. Analyst sentiment remains positive with 58.5% buy ratings, though the consensus price target of $95 suggests caution. Recent developments include new product launches in sugar separation technology and Tyvek innovations, alongside ongoing PFAS litigation settlements.
The outlook for DD hinges on margin recovery and growth in key sectors like healthcare and water technologies, but investors face risks from legal liabilities, volatile cash flows, and high P/E valuation. Institutional activity shows mixed signals with both position reductions and significant increases, reflecting uncertainty about near-term performance amid structural growth opportunities.
Medtronic (MDT) trades at $85.51, down 1.81% on the day, showing bearish technical signals despite strong fundamental performance. The company has beaten earnings estimates for three consecutive quarters with Q3 2026 results pending, while maintaining robust profitability margins of 65% gross and 14% net. Recent news highlights the company's 49-year dividend growth streak and new product approvals, though technical indicators show selling pressure with the stock trading near support at $85.
MDT presents a compelling value opportunity with a 3.2% dividend yield and 14% upside to the $97.80 consensus target, though near-term technical weakness and increasing debt levels warrant caution. The company's consistent earnings beats and medical device market leadership support long-term growth, while regulatory approvals for new systems provide catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DuPont de Nemours Inc
DuPont is a diversified global specialty chemicals company created in 2019 as a result of the DowDuPont merger and subsequent separations. Its portfolio includes specialty chemicals and downstream products that serve the electronics and communication, automotive, construction, safety and protection, and water management industries. DuPont benefits from the ability to produce patented specialty chemicals that command pricing power. Noteworthy products include Kevlar, Tyvek, and Nomex have evolved over time to enable a wide range of applications across multiple industries.
Read more on DD →About Medtronic PLC
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →
